Genprex Inc stock rises after crossing above key SMA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 22 Jan 26
Source: Coinmarketcap
Genprex Inc's stock price increased by 5.65% after crossing above its 5-day SMA, indicating positive momentum in the market.
The rise in Genprex's stock is attributed to broad market strength, as both the Nasdaq-100 and S&P 500 indices are showing gains of 0.76% and 0.63%, respectively. This upward movement reflects a favorable environment for growth stocks, contributing to Genprex's performance.
Investors are optimistic about Genprex's future prospects, especially in light of the overall market conditions that favor biotech and healthcare sectors.
Analyst Views on GNPX
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
